Seema Nagpal

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
    Seema Nagpal
    Division of Neuro Oncology, Department of Neurology, Stanford University, 875 Blake Wilbur Drive CC2221, Stanford, CA, 94305, USA
    J Neurooncol 123:277-82. 2015
  2. pmc Bevacizumab improves quality of life in patients with recurrent glioblastoma
    Seema Nagpal
    Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Chemother Res Pract 2011:602812. 2011
  3. pmc Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
    Reena P Thomas
    Department of Neurological Sciences, Stanford University Hospital, Stanford, CA, USA
    Clin Pharmacol 5:1-9. 2013
  4. doi request reprint Treatment of leptomeningeal spread of NSCLC: a continuing challenge
    Seema Nagpal
    Department of Neurology, Division of Neuro Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive CC2221, Stanford, CA 94305, USA
    Curr Treat Options Oncol 13:491-504. 2012
  5. doi request reprint The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma
    Seema Nagpal
    Division of Neuro Oncology, Department of Neurology, Stanford Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221, Stanford, CA 94305 5826, USA
    Neurosurg Clin N Am 23:289-95, ix. 2012
  6. doi request reprint Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain
    Jalal B Andre
    Department of Radiology, University of Washington Seattle, WA, USA Department of Radiology, Stanford University, Stanford, CA, USA
    Neuroradiol J 28:112-9. 2015
  7. doi request reprint Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT
    Andrei Iagaru
    From the Division of Nuclear Medicine and Molecular Imaging A I, C M, E M, Department of Radiology, Neuroradiology Section G Z, N F, Division of Neurosurgery G H, G L, and Division of Neuro Oncology S N, L R, Stanford University Medical Center, 300 Pasteur Dr, Room H 2200, Stanford, CA 94305 and Departments of Radiology, Bioengineering, Materials Science, and Engineering, Stanford University School of Medicine, Stanford, Calif S S G
    Radiology 277:497-506. 2015
  8. pmc Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI
    Heiko Schmiedeskamp
    Lucas Center, Department of Radiology, Stanford University, Stanford, California 94305 5488, USA
    J Cereb Blood Flow Metab 33:732-43. 2013
  9. doi request reprint The incidence and significance of multiple lesions in glioblastoma
    Reena P Thomas
    Department of Neurology, Stanford University Hospital, 300 Pasteur Drive, Room A343, Palo Alto, CA 94304 5235, USA
    J Neurooncol 112:91-7. 2013

Collaborators

Detail Information

Publications9

  1. doi request reprint Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
    Seema Nagpal
    Division of Neuro Oncology, Department of Neurology, Stanford University, 875 Blake Wilbur Drive CC2221, Stanford, CA, 94305, USA
    J Neurooncol 123:277-82. 2015
    ..Hematologic toxicity was mild. Three patients had confirmed partial responses according to RANO criteria. These clinical data combined with a favorable safety profile warrant further clinical investigation of this agent in HGG...
  2. pmc Bevacizumab improves quality of life in patients with recurrent glioblastoma
    Seema Nagpal
    Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Chemother Res Pract 2011:602812. 2011
    ..2 months (P < 0.001, log rank survival) in the NoBEV group. Conclusions. BEV increases independent living and lengthens overall survival after GBM recurrence. Reduction in steroid dose may contribute to prolonged independence...
  3. pmc Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
    Reena P Thomas
    Department of Neurological Sciences, Stanford University Hospital, Stanford, CA, USA
    Clin Pharmacol 5:1-9. 2013
    ....
  4. doi request reprint Treatment of leptomeningeal spread of NSCLC: a continuing challenge
    Seema Nagpal
    Department of Neurology, Division of Neuro Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive CC2221, Stanford, CA 94305, USA
    Curr Treat Options Oncol 13:491-504. 2012
    ..The use of antidepressants, central nervous system stimulants, benzodiazepines, antiemetics, and pain medications can increase quality of life in patients with leptomeningeal metastases...
  5. doi request reprint The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma
    Seema Nagpal
    Division of Neuro Oncology, Department of Neurology, Stanford Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221, Stanford, CA 94305 5826, USA
    Neurosurg Clin N Am 23:289-95, ix. 2012
    ..However, the rate of complications, including an increase in cerebrospinal fluid leaks and intracranial hypertension, has limited their use. This article reviews the current data for use of BCNU wafers in malignant gliomas...
  6. doi request reprint Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain
    Jalal B Andre
    Department of Radiology, University of Washington Seattle, WA, USA Department of Radiology, Stanford University, Stanford, CA, USA
    Neuroradiol J 28:112-9. 2015
    ..4 vs. 41 ± 8.4 ml/100 g/min, p = 0.03). The decrease in mean CBF tended to be greater in the tumoral region than in the contralateral MCA, though the difference did not reach statistical significance (31% vs. 13%; p = 0.082)...
  7. doi request reprint Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT
    Andrei Iagaru
    From the Division of Nuclear Medicine and Molecular Imaging A I, C M, E M, Department of Radiology, Neuroradiology Section G Z, N F, Division of Neurosurgery G H, G L, and Division of Neuro Oncology S N, L R, Stanford University Medical Center, 300 Pasteur Dr, Room H 2200, Stanford, CA 94305 and Departments of Radiology, Bioengineering, Materials Science, and Engineering, Stanford University School of Medicine, Stanford, Calif S S G
    Radiology 277:497-506. 2015
    ....
  8. pmc Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI
    Heiko Schmiedeskamp
    Lucas Center, Department of Radiology, Stanford University, Stanford, California 94305 5488, USA
    J Cereb Blood Flow Metab 33:732-43. 2013
    ..Furthermore, extracted permeability parameters were in good agreement with elevated T1-weighted postcontrast signal values...
  9. doi request reprint The incidence and significance of multiple lesions in glioblastoma
    Reena P Thomas
    Department of Neurology, Stanford University Hospital, 300 Pasteur Drive, Room A343, Palo Alto, CA 94304 5235, USA
    J Neurooncol 112:91-7. 2013
    ..The rate of multiple lesions reported here may be the result of improved imaging technology, suggesting that incidence of multiple lesions will continue to increase as imaging technology advances...